Sarcopenia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
The Sarcopenia Treatment Market size is estimated at USD 3.07 billion in 2024, and is expected to reach USD 4.02 billion by 2029, growing at a CAGR of 4.48% during the forecast period (2024-2029).
Factors such as the rise in the geriatric population and the increase in malnutrition, coupled with vitamin deficiency globally, are expected to increase the need for sarcopenia treatment, fueling the market growth over the study period. For instance, according to a study published in August 2022 in Nutrients Journal, older people had a higher risk of developing Sarcopenia, emphasizing the need for proper treatment and nutrition intake. Moreover, according to the World Population Prospects 2022 report by the United Nations, the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. As the senior population is more prone to acquiring muscle issues due to their age, the demand for sarcopenia treatment is expected to increase with the aging population, contributing to market growth over the study period.
Additionally, an increase in research studies and pipeline assets by the key players focusing on sarcopenia treatment is expected to augment the market growth over the study period. For instance, Research Square's article published in February 2022 highlighted the association of Sarcopenia with vitamin D, protein, and calcium intake. Among these nutrients, calcium has the most significant impact. Also, an article published by the Examine in January 2022 examined the association between vitamin B12 and muscle health in older adults. In this study, the investigators assessed several markers of muscle health, including appendicular (legs and arms) skeletal muscle mass, handgrip strength, and performance on a physical test battery. The study compared the vitamin B12 insufficiency associated with low appendicular skeletal muscle mass. Hence, the increased adoption of Vitamin B12, Calcium and Vitamin D among older patients in treating Sarcopenia will likely boost the market growth.
Furthermore, a low-quality diet and muscle weakness are significant factors contributing to Sarcopenia. Increasing the uptake of proper nutrition and vitamins may significantly reduce the risk of Sarcopenia.
According to an article published by Frontiers in Endocrinology in June 2022, vitamin D supplementation improved handgrip strength in postmenopausal women. The supplement did not improve mobility but enhanced muscle strength, particularly in postmenopausal women over 60 without calcium supplementation or whose baseline vitamin D is >75 nmol/L (30 ng/ml). Hence, such research studies depicting the importance of nutritional intake in treating Sarcopenia are expected to drive market growth over the forecast period.
Thus, due to the increase in the geriatric population, the rise in research studies to develop sarcopenia treatment products, and the surge in advantages offered by sarcopenia treatment products, the market studied is expected to witness significant growth over the study period. However, the non-availability of new drugs will hinder the market's growth over the forecast period.
Sarcopenia Treatment Market Trends
Protein Supplement Anticipated to Show Considerable Growth During the Forecast Period
Protein is a critical macronutrient for the maintenance of normal bodily functions. Daily protein intake varies by age, sex, and degree of daily activity but is essential to maintaining muscle mass and strength throughout an individual's lifespan. Therefore, increasing protein intake in the diet prevents the loss of muscle mass, thus driving the market.
The growing research and development activities are helping to identify the protein dosage required to fulfill the protein deficiency in the body, and treating sarcopenia is likely to drive segment growth. For instance, an article published in March 2022 stated that protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries.
Furthermore, according to the study published in March 2022 in PubMed, protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries. Hence, studies demonstrating the use of protein supplements in sarcopenia are expected to drive market growth over the forecast period. Moreover, strategic activities by the key players and awareness regarding the importance of sarcopenia treatments are expected to boost market growth. For instance, in July 2022, World Sarcopenia Day was celebrated worldwide, and it serves as an opportunity to raise awareness and knowledge for the prevalent disease, sarcopenia. Hence, the growing awareness among consumers regarding the diseases would increase the demand for protein supplements and products.
Several companies invest in research and development activities to provide innovative protein powder products catering to consumers’ preferences. For instance, the availability of protein powders that are plant-based, lactose-free, or specifically designed for women or athletes has increased in recent years. In October 2022, Tata Consumer Products (TCP), a part of Tata Group, expanded into the health supplements segment by introducing ‘Tata GoFit,’ a plant-based protein powder product designed for health-conscious women.
Hence, the studied segment is expected to witness significant growth over the forecast period due to the increased research and development and the key players' strategic activities.
North America Anticipated to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant position in the sarcopenia treatment market, owing to the presence of developed healthcare facilities and technological advancements that are likely to fuel the growth of the sarcopenia treatment market during the forecast period.
Furthermore, an increase in the geriatric population in North America is expected to bolster market growth over the forecast period. For instance, according to the Statistics Canada July 2022 update, as of July 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Thus, the geriatric population is more prone to sarcopenia and other muscle-related diseases; the rise in the geriatric population is expected to increase the need for sarcopenia treatment, driving the market growth over the forecast period.
Furthermore, various clinical studies are widely conducted in the North American region to demonstrate the efficacy of supplements in sarcopenia treatments. For instance, in April 2022, the University of Arkansas sponsored a clinical trial to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), to determine the state of muscle health. For that purpose, trial subjects were given 10 g of a commercially available nutritional supplement for sarcopenia. Hence, an increase in such clinical studies demonstrating the clinical outcome of supplements to treat sarcopenia may result in the launch of new supplements and thus may contribute to the growth of the studied market in the region.
Moreover, various government initiatives support research and development of sarcopenia treatments, further contributing to market growth. For instance, according to the article published in February 2022 in PubMed, the United States Department of Health and Human Services was one of the leading funding organizations that sponsored 1,604 sarcopenia-related articles. The United States is a significant country in the North American region that contributes more toward sarcopenia-related research and development. This increased research is anticipated to lead to various innovations in the country, driving the growth of the sarcopenia treatment market in the country.
Thus, due to the increase in the geriatric population and the rise in strategic activities by the government and key players, North America is expected to witness significant growth over the forecast period.
Sarcopenia Treatment Industry Overview
The sarcopenia treatment market is semi-consolidated in nature. The key manufacturers in the sarcopenia treatment market have been focusing on a clinical study to strengthen portfolios for the treatment of sarcopenia. A few key market players in the market studied are Nestlй SA, Sanofi SA, Novastis AG, Eli Lilly and Company and Bayer AG. These companies are involved in various strategic initiatives such as mergers, collaborations, acquisitions, etc.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
Factors such as the rise in the geriatric population and the increase in malnutrition, coupled with vitamin deficiency globally, are expected to increase the need for sarcopenia treatment, fueling the market growth over the study period. For instance, according to a study published in August 2022 in Nutrients Journal, older people had a higher risk of developing Sarcopenia, emphasizing the need for proper treatment and nutrition intake. Moreover, according to the World Population Prospects 2022 report by the United Nations, the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. As the senior population is more prone to acquiring muscle issues due to their age, the demand for sarcopenia treatment is expected to increase with the aging population, contributing to market growth over the study period.
Additionally, an increase in research studies and pipeline assets by the key players focusing on sarcopenia treatment is expected to augment the market growth over the study period. For instance, Research Square's article published in February 2022 highlighted the association of Sarcopenia with vitamin D, protein, and calcium intake. Among these nutrients, calcium has the most significant impact. Also, an article published by the Examine in January 2022 examined the association between vitamin B12 and muscle health in older adults. In this study, the investigators assessed several markers of muscle health, including appendicular (legs and arms) skeletal muscle mass, handgrip strength, and performance on a physical test battery. The study compared the vitamin B12 insufficiency associated with low appendicular skeletal muscle mass. Hence, the increased adoption of Vitamin B12, Calcium and Vitamin D among older patients in treating Sarcopenia will likely boost the market growth.
Furthermore, a low-quality diet and muscle weakness are significant factors contributing to Sarcopenia. Increasing the uptake of proper nutrition and vitamins may significantly reduce the risk of Sarcopenia.
According to an article published by Frontiers in Endocrinology in June 2022, vitamin D supplementation improved handgrip strength in postmenopausal women. The supplement did not improve mobility but enhanced muscle strength, particularly in postmenopausal women over 60 without calcium supplementation or whose baseline vitamin D is >75 nmol/L (30 ng/ml). Hence, such research studies depicting the importance of nutritional intake in treating Sarcopenia are expected to drive market growth over the forecast period.
Thus, due to the increase in the geriatric population, the rise in research studies to develop sarcopenia treatment products, and the surge in advantages offered by sarcopenia treatment products, the market studied is expected to witness significant growth over the study period. However, the non-availability of new drugs will hinder the market's growth over the forecast period.
Sarcopenia Treatment Market Trends
Protein Supplement Anticipated to Show Considerable Growth During the Forecast Period
Protein is a critical macronutrient for the maintenance of normal bodily functions. Daily protein intake varies by age, sex, and degree of daily activity but is essential to maintaining muscle mass and strength throughout an individual's lifespan. Therefore, increasing protein intake in the diet prevents the loss of muscle mass, thus driving the market.
The growing research and development activities are helping to identify the protein dosage required to fulfill the protein deficiency in the body, and treating sarcopenia is likely to drive segment growth. For instance, an article published in March 2022 stated that protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries.
Furthermore, according to the study published in March 2022 in PubMed, protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries. Hence, studies demonstrating the use of protein supplements in sarcopenia are expected to drive market growth over the forecast period. Moreover, strategic activities by the key players and awareness regarding the importance of sarcopenia treatments are expected to boost market growth. For instance, in July 2022, World Sarcopenia Day was celebrated worldwide, and it serves as an opportunity to raise awareness and knowledge for the prevalent disease, sarcopenia. Hence, the growing awareness among consumers regarding the diseases would increase the demand for protein supplements and products.
Several companies invest in research and development activities to provide innovative protein powder products catering to consumers’ preferences. For instance, the availability of protein powders that are plant-based, lactose-free, or specifically designed for women or athletes has increased in recent years. In October 2022, Tata Consumer Products (TCP), a part of Tata Group, expanded into the health supplements segment by introducing ‘Tata GoFit,’ a plant-based protein powder product designed for health-conscious women.
Hence, the studied segment is expected to witness significant growth over the forecast period due to the increased research and development and the key players' strategic activities.
North America Anticipated to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant position in the sarcopenia treatment market, owing to the presence of developed healthcare facilities and technological advancements that are likely to fuel the growth of the sarcopenia treatment market during the forecast period.
Furthermore, an increase in the geriatric population in North America is expected to bolster market growth over the forecast period. For instance, according to the Statistics Canada July 2022 update, as of July 2022, almost one in five Canadians (18.8% of the population; 7,329,910 people) were at least 65 years of age. Thus, the geriatric population is more prone to sarcopenia and other muscle-related diseases; the rise in the geriatric population is expected to increase the need for sarcopenia treatment, driving the market growth over the forecast period.
Furthermore, various clinical studies are widely conducted in the North American region to demonstrate the efficacy of supplements in sarcopenia treatments. For instance, in April 2022, the University of Arkansas sponsored a clinical trial to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), to determine the state of muscle health. For that purpose, trial subjects were given 10 g of a commercially available nutritional supplement for sarcopenia. Hence, an increase in such clinical studies demonstrating the clinical outcome of supplements to treat sarcopenia may result in the launch of new supplements and thus may contribute to the growth of the studied market in the region.
Moreover, various government initiatives support research and development of sarcopenia treatments, further contributing to market growth. For instance, according to the article published in February 2022 in PubMed, the United States Department of Health and Human Services was one of the leading funding organizations that sponsored 1,604 sarcopenia-related articles. The United States is a significant country in the North American region that contributes more toward sarcopenia-related research and development. This increased research is anticipated to lead to various innovations in the country, driving the growth of the sarcopenia treatment market in the country.
Thus, due to the increase in the geriatric population and the rise in strategic activities by the government and key players, North America is expected to witness significant growth over the forecast period.
Sarcopenia Treatment Industry Overview
The sarcopenia treatment market is semi-consolidated in nature. The key manufacturers in the sarcopenia treatment market have been focusing on a clinical study to strengthen portfolios for the treatment of sarcopenia. A few key market players in the market studied are Nestlй SA, Sanofi SA, Novastis AG, Eli Lilly and Company and Bayer AG. These companies are involved in various strategic initiatives such as mergers, collaborations, acquisitions, etc.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population
4.2.2 Rise in Malnutrition and Vitamin Deficiency in Developing Countries
4.3 Market Restraints
4.3.1 Non-availability of New Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE - USD)
5.1 By Treatment Type
5.1.1 Protein Supplements
5.1.2 Vitamin B12 Supplements
5.1.3 Vitamin D and Calcium Supplements
5.1.4 Other Treatment Types
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.2.4 Other Distribution Channels
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East &Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Nestle Health Science
6.1.2 Sanofi SA
6.1.3 Bayer AG
6.1.4 Novartis AG
6.1.5 Zydus Life Sciences Limited
6.1.6 Eli Lilly and Company
6.1.7 Haleon Group of Companies
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population
4.2.2 Rise in Malnutrition and Vitamin Deficiency in Developing Countries
4.3 Market Restraints
4.3.1 Non-availability of New Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE - USD)
5.1 By Treatment Type
5.1.1 Protein Supplements
5.1.2 Vitamin B12 Supplements
5.1.3 Vitamin D and Calcium Supplements
5.1.4 Other Treatment Types
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.2.4 Other Distribution Channels
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East &Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Nestle Health Science
6.1.2 Sanofi SA
6.1.3 Bayer AG
6.1.4 Novartis AG
6.1.5 Zydus Life Sciences Limited
6.1.6 Eli Lilly and Company
6.1.7 Haleon Group of Companies
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
